Stock 1541 IMMUNEONCO BIOPHARMACEUTICALS (SHANGHAI) INC.
Add to a list
To use this feature you must be a member
Log inSign up

Revisions ImmuneOnco Biopharmaceuticals (Shanghai) Inc.

Equities

1541

CNE100006624

Delayed Hong Kong S.E.
Other stock markets
 12:15:47 20/05/2024 pm IST 		5-day change 1st Jan Change
14.74 HKD +1.66% Intraday chart for ImmuneOnco Biopharmaceuticals (Shanghai) Inc. +2.93% -50.70%
17/05 Immuneonco Biopharmaceuticals Gets Regulatory Go-Ahead for Phase 3 Trial of Myelodysplastic Syndrome Drug in China MT
17/05 Immuneonco Biopharmaceuticals Inc. Receives Approval from the Center for Drug Evaluation of the National Medical Products Administration of the People's Republic of China for A Randomized, Double-Blind, Controlled Phase III Clinical Trial of MM01 (Timdarpacept) in Combination with Azacitidine for the First-Line Treatment of Higher-Risk Myelodysplastic Syndrome (HR MDS) CI

Turnover - Change in analysts' estimates

EBIT - Change in analysts' estimates

Dividend / Share (DPS) - Change in analysts' estimates

Cash or Net Debt - Change in analysts' estimates

Turnover

EBIT

Dividend / Share (DPS)

Cash or Net Debt

  1. Stock Market
  2. Equities
  3. 1541 Stock
  4. Revisions ImmuneOnco Biopharmaceuticals (Shanghai) Inc.
-40% Exceptional extension: Our subscriptions help you unlock the best investment opportunities.
BENEFIT NOW